Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: AA Clear all
Enrolling by invitation No phase listed Observational

Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)

NCT06433622
View directory record Official record
Conditions
Traumatic Intracranial Hemorrhage
Interventions
Repeat Thromboelastography with Platelet Mapping
Diagnostic Test
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 4, 2026, 5:44 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension

NCT04937959
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Normal Cognition
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Sep 4, 2026, 5:44 AM EDT
Recruiting Not applicable Interventional

Integrated Treatment for Enhancing Growth in Recovery During Adolescence

NCT06395467
View directory record Official record
Conditions
Alcohol Use Disorder, Cannabis Use Disorder
Interventions
InTEGRA, MET/CBT
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 21 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Farmington, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 4, 2026, 5:44 AM EDT
Not listed Not applicable Interventional

BFR DISTRAD NON OP: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture

NCT03056950
View directory record Official record
Conditions
Distal Radius Fracture, Rehabilitation
Interventions
DELFI PTS ii portable tourniquet
Device
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

AA Linkage for Alcohol Abusing Women Leaving Jail

NCT01970293
View directory record Official record
Conditions
Alcohol Use, AA Attendance, Sexual Risk Behavior
Interventions
Introduction to AA volunteer
Other
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

NCT04704154
View directory record Official record
Conditions
Solid Tumors
Interventions
Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 4, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

NCT02800486
View directory record Official record
Conditions
Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma, Brain Neoplasm, Brain Cancer, Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Malignant
Interventions
Intra-arterial Cetuximab, Intra-arterial Mannitol, Hypofractionated re-irradiation
Drug · Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 4, 2026, 5:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

African-American Bone Metabolism and Lactation Study

NCT00785824
View directory record Official record
Conditions
Lactation, Bone Diseases, Endocrine
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

NCT02138747
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Tolterodine ER
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 4, 2026, 5:44 AM EDT
Terminated Not applicable Interventional

Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States

NCT00038779
View directory record Official record
Conditions
Leukemia, Non Hodgkin's Lymphoma, Aplastic Anemia
Interventions
Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 49 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Synapse Project

NCT04871074
View directory record Official record
Conditions
Alzheimer Disease
Interventions
UCB-J, MRI Scan, PET Scan
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 1 Interventional

Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

NCT01985256
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
Interventions
Toca 511, Toca FC
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced Sep 4, 2026, 5:44 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

The LEADS Trial (Linking Exericise for Advancing Daily Stress Management)

NCT07176234
View directory record Official record
Conditions
Physical Activity, Childhood Obesity
Interventions
Treatment, Health Education
Behavioral · Other
Lead sponsor
University of South Carolina
Other
Eligibility
11 Years to 16 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Columbia, South Carolina • Sumter, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

NCT02025010
View directory record Official record
Conditions
Castration-resistant Prostate Cancer
Interventions
abiraterone acetate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
8
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults

NCT00516035
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Sep 4, 2026, 5:44 AM EDT
Terminated Not applicable Interventional

Building Self-regulation Capacity in AA T2DM Women: Feasibility of EMI

NCT04083248
View directory record Official record
Conditions
Type 2 Diabetes, Self-regulation
Interventions
Feasibility group
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 4, 2026, 5:44 AM EDT
Completed No phase listed Observational

Observational Assessment of Baseline Asthma Control in African-American Children

NCT01891630
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Not applicable Interventional

EAA Intake to Optimize Protein Anabolism in COPD

NCT01173354
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Free balanced amino acid mixture, Free essential amino acid mixture
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Women's Walking Program

NCT01700894
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Walking Program + Motivational Interviewing Calls, Walking Program + Automated Calls, Walking Program
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Chicago, Illinois • Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Sep 4, 2026, 5:44 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension

NCT04951284
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Early Phase 1 Interventional

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

NCT02320305
View directory record Official record
Conditions
Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 4, 2026, 5:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Network Intervention for Reducing Sexual Risk for HIV With African American Men Who Have Sex With Men (AA MSM)

NCT00691041
View directory record Official record
Conditions
HIV Infections
Interventions
Unity in Diversity
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Male only
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Sep 4, 2026, 5:44 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Machine Learning Technology in Predicting Relapse and Implementing Peer Recovery Intervention Before Drug Use Occurs

NCT05976672
View directory record Official record
Conditions
Substance Abuse Disorder
Interventions
PRSS (Peer Recovery Support Specialist)
Other
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 4, 2026, 5:44 AM EDT
Recruiting Not applicable Interventional

OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)

NCT05293756
View directory record Official record
Conditions
Hypertension, Self-Management, Technology, Quality of Life
Interventions
OPTIMA-BP Intervention
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
50 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 4, 2026, 5:44 AM EDT